arrow
V

Vito Baraka

national institute for medical research
H指数:21
被引数:1,589

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomic profiling of drug resistance markers in Plasmodium falciparum samples from the Democratic Republic of the Congo (2017) and Tanzania (2020–2021)

刚果民主共和国(2017年)和坦桑尼亚(2020–2021年)恶性疟原虫样本中药物抗性标记物的基因组分析

2026-09-010
OAAI
Harnessing genomic and bioinformatics for surveillance of pathogens in Africa: a scoping review of existing training and gaps in training

利用基因组学和生物信息学对非洲病原体进行监测:现有培训及其培训缺口的范围综述

2026-05-290
OAAI
Spatio-temporal modelling and prediction of Anopheles mosquito abundance in Tanga and Unguja, Tanzania: climatic drivers and insights for malaria early warning and vector control strategies

坦桑尼亚塔纳加和翁古贾地区按蚊数量的时空建模与预测:气候驱动因素及对疟疾早期预警和媒介控制策略的启示

2026-02-200
PRE
Severe malaria treatment with rectal artesunate and artemisinin-based combination therapy in remote settings: an effectiveness-implementation hybrid type 3 study protocol (SEMA ReACT)

偏远地区使用直肠青蒿素和青蒿素为基础的联合疗法治疗重症疟疾:一项效果-实施混合型3类研究方案(SEMA ReACT)

2026-02-090
PRE
Implementation of the intermittent preventive treatment of malaria in school-aged children (IPTsc) in moderate and high endemic areas in Tanzania: a policy brief

在坦桑尼亚中等和高疟疾流行区对学龄儿童间歇性预防性治疗(IPTsc)的实施:政策简报

2025-11-180
OAAI
Implementation and effectiveness of intermittent preventive treatment in school aged children using dihydroartemisinin-piperaquine to reduce malaria burden: an implementation research of a cluster randomised trial in Tanzania

使用双氢青蒿素哌喹间歇预防性治疗以降低疟疾负担:坦桑尼亚一项整群随机试验的实施研究——实施与有效性

2025-11-070
OAAI
Strengthening pathogen and antimicrobial resistance surveillance through environmental monitoring in sub-Saharan Africa: stakeholder perspectives

通过环境监测加强撒哈拉以南非洲的病原体和抗菌药物耐药性监测:利益相关者视角

2025-09-020
OAAI
A novel intron variant is associated with emerging pfdhps mutant haplotypes in West and Central African Plasmodium falciparum

一种新型内含子变异与西非和中非恶性疟原虫中出现的pfdhps突变单倍型相关联

2025-08-260
OAAI
Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial
2017-01-0114
OAAI
Genomic epidemiology of artemisinin resistant malaria
2016-03-04242
OA